WO2008070344A2 - Compositions and methods for binding sphingosine-1-phosphate - Google Patents

Compositions and methods for binding sphingosine-1-phosphate Download PDF

Info

Publication number
WO2008070344A2
WO2008070344A2 PCT/US2007/082647 US2007082647W WO2008070344A2 WO 2008070344 A2 WO2008070344 A2 WO 2008070344A2 US 2007082647 W US2007082647 W US 2007082647W WO 2008070344 A2 WO2008070344 A2 WO 2008070344A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
percent
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/082647
Other languages
English (en)
French (fr)
Other versions
WO2008070344A3 (en
WO2008070344A9 (en
Inventor
Roger A. Sabbadini
William A. Garland
Genevieve Hansen
Steven Tarran Jones
David Gareth Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollo Endosurgery Inc
Lpath Therapeutics Inc
Original Assignee
Apollo Endosurgery Inc
Lpath Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009004532A priority Critical patent/MX2009004532A/es
Priority to CA002667574A priority patent/CA2667574A1/en
Priority to CN200780048665.8A priority patent/CN101679506B/zh
Priority to PL07871262T priority patent/PL2087002T3/pl
Priority to EP07871262.7A priority patent/EP2087002B1/en
Priority to DK07871262.7T priority patent/DK2087002T3/da
Priority to ES07871262.7T priority patent/ES2524059T3/es
Priority to AU2007329759A priority patent/AU2007329759B2/en
Priority to JP2009534885A priority patent/JP5795833B2/ja
Priority to SI200731525T priority patent/SI2087002T1/sl
Priority to BRPI0718118A priority patent/BRPI0718118A2/pt
Application filed by Apollo Endosurgery Inc, Lpath Therapeutics Inc filed Critical Apollo Endosurgery Inc
Publication of WO2008070344A2 publication Critical patent/WO2008070344A2/en
Publication of WO2008070344A9 publication Critical patent/WO2008070344A9/en
Priority to US12/258,346 priority patent/US8222373B2/en
Priority to US12/258,353 priority patent/US7956173B2/en
Priority to US12/258,337 priority patent/US8067549B2/en
Priority to US12/258,355 priority patent/US8025877B2/en
Priority to US12/258,383 priority patent/US8026342B2/en
Publication of WO2008070344A3 publication Critical patent/WO2008070344A3/en
Priority to IL198379A priority patent/IL198379A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Definitions

  • Lipid signaling pathways are activated by a variety of extracellular stimuli, ranging from growth factors to inflammatory cytokines, and regulate cell fate decisions such as apoptosis, differentiation and proliferation.
  • Research into bioactive lipid signaling is an area of intense scientific investigation as more and more bioactive lipids are identified and their actions characterized.
  • N-acylsphingosines (ceramides) [SP0201] N-acylsphinganines (dihydroceramides) [SP0202]
  • variable region comprises framework and CDRs (otherwise known as hypervariables) and refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework region (FR).
  • FR framework region
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • framework region (FR) residues of the human immunoglobulin are replaced by corresponding non- human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • what constitutes a therapeutically effective amount of a particular active ingredient may differ from what constitutes a therapeutically effective amount of the active ingredient when administered as a monotherapy (ie., a therapeutic regimen that employs only one chemical entity as the active ingredient).
  • Example 12 An example of this form of affinity maturation is shown in Example 12, below, where a cysteine residue in a heavy chain CDR was changed by site-directed mutagenesis to an alanine residue, resulting in a substantial increase in S IP-binding affinity and stability.
  • the variable region included the amino acid sequence ofSEQ ID NO:27.
  • Such heavy chain variable domain sequences in CDRH2 can optionally be combined with a light chain variable domain, for example, a light chain variable comprising the amino acid sequence of SEQ ID NO: 17, or preferably the light chain variable domain amino acid sequence of SEQ ID NO:30.
  • isolated antibody molecules are provided that contain precisely defined CDR sequences in each heavy chain and each light chain.
  • the isolated antibody molecule is a humanized antibody molecule.
  • Figure 11 presents data showing the binding properties of several murine, chimeric, and recombinant humanized anti-SIP antibodies.
  • the binding to SlP for the mouse (muMAbSIP; curve generated from square data points) and chimeric (chMAb SlP; curve generated from upright triangular data points) were compared in an ELISA binding assay to the first version of the humanized antibody (pATH200 + pATH300; curve generated from inverted triangular data points).
  • a “hapten” refers to a small molecule that can, under most circumstances, elicit an immune response (i.e., act as an antigen) only when attached to a carrier molecule, for example, a protein, polyethylene glycol (PEG), colloidal gold, silicone beads, and the like.
  • the carrier may be one that also does not elicit an immune response by itself.
  • antibody is used in the broadest sense, and encompasses monoclonal, polyclonal, multispecific (e.g., bispecific, wherein each arm of the antibody is reactive with a different epitope or the same or different antigen), minibody, heteroconjugate, diabody, triabody, chimeric, and synthetic antibodies, as well as antibody fragments that specifically bind an antigen with a desired binding property and/or biological activity.
  • Cancer is now primarily treated with one or a combination of three types of therapies, surgery, radiation, and chemotherapy.
  • Surgery involves the bulk removal of diseased tissue. While surgery is sometimes effective in removing tumors located at certain sites, for example, in the breast, colon, and skin, it cannot be used in the treatment of tumors located in other areas, such as the backbone, nor in the treatment of disseminated neoplastic conditions such as leukemia.
  • mAbs monoclonal antibodies
  • Approved therapeutic mAbs include Avastin®, Erbitux®, and Rituxan®. Additional mAbs are in various phases of clinical development for a variety of diseases with the majority targeting various forms of cancer.
  • monoclonal antibodies are generated in non- human mammals.
  • the therapeutic utility of murine monoclonal antibodies is limited, however, principally due to the fact that human patients mount their own antibody response to murine antibodies. This response, the so-called HAMA (human anti-mouse antibody) response, results in the eventual neutralization and rapid elimination of murine mAbs.
  • HAMA human anti-mouse antibody
  • bFGF basic fibroblastic growth factor
  • Sphingosine-1 -Phosphate is a bioactive lyso lipid with pleotrophic effects. It is pro- angiogenic, pro inflammatory (stimulates the recruitment of macrophages and mast cells) and pro-fibrotic (stimulates scar formation). SlP generally stimulates cells to proliferate and migrate and is anti-apoptotic. SlP achieves these biologically diverse functions through its interactions with numerous cytokines and growth factors. Inhibition of SlP via a monoclonal antibody (SPHINGOMAB) has been demonstrated to block the functions of vascular endothelial growth factor (VEGF), bFGF, IL-6, and IL-8 [Visentin, B et al.
  • VEGF vascular endothelial growth factor
  • bFGF vascular endothelial growth factor
  • IL-6 IL-6
  • IL-8 vascular endothelial growth factor
  • SlP produced locally by damaged cells could be responsible for the maladaptive wound healing associated with remodeling and scar formation.
  • SlP inhibitors are useful in diseases or conditions characterized, at least in part, by aberrant fibrogenesis or fibrosis.
  • the formation of subretinal fibrosis leads to irreversible damage to the photoreceptors and permanent vision loss.
  • the potential for subretinal fibrosis and future vision loss persists.
  • Topical drops are convenient, but wash away primarily because of nasolacrimal drainage often delivering less than 5% of the applied drug into the anterior section of the eye and an even smaller fraction of that dose to the posterior segment of the globe.
  • sprays afford another mode for topical administration.
  • a third mode is ophthalmic ointments or emulsions can be used to prolong the contact time of the formulation with the ocular surface although blurring of vision and matting of the eyelids can be troublesome.
  • the antibody may be one that reduce angiogenesis and alter tumor progression.
  • the antibody has an effective concentration 50 (EC50) value of no more than about 10 ug/ml, preferably no more than about 1 ug/ml, and most preferably no more than about 0.1 ug/ml, as measured in a direct binding ELISA assay.
  • the human variable light FR sequence preferably has substitutions therein, e.g., wherein a human FR residue is replaced by a corresponding mouse residue, but replacement with the nonhuman residue is not necessary.
  • a replacement residue other than the corresponding nonhuman residue may be selected by phage display.
  • Exemplary variable light FR residues that may be substituted include any one or more of FR residue numbers, including, but not limited to, F4, Y36, Y49, G64, S67. With respect to the CDRs, these preferably have amino acid sequences listed in Table 2, below.
  • nonhuman anti-sphingolipid antibodies Methods for humanizing nonhuman anti-sphingolipid antibodies and generating variants of anti-sphingolipid antibodies are described in the Examples below.
  • the nonhuman antibody starting material is prepared.
  • the parent antibody is prepared. Exemplary techniques for generating such nonhuman antibody starting material and parent antibodies will be described in the following sections.
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbant assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbant assay
  • insertional variants of the anti-sphingolipid antibody molecule include the fusion to the N- or C-terminus of the anti-sphingolipid antibody of an enzyme or a polypeptide which increases the serum half-life of the antibody.
  • Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the anti-sphingolipid antibody molecule removed and a different residue inserted in its place.
  • the sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary" substitutions listed below, or as further described below in reference to amino acid classes, may be introduced and the products screened.
  • cysteine residues not involved in maintaining the proper conformation of the humanized or variant anti-sphingo lipid antibody also may be substituted, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.
  • cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
  • an antibody (or polymer or polypeptide) of the invention comprising one or more binding sites per arm or fragment thereof will be referred to herein as "multivalent” antibody.
  • a "bivalent” antibody of the invention comprises two binding sites per Fab or fragment thereof whereas a “trivalent” polypeptide of the invention comprises three binding sites per Fab or fragment thereof.
  • the two or more binding sites per Fab may be binding to the same or different antigens.
  • the antibody typically will be labeled with a detectable moiety.
  • a detectable moiety Numerous labels are available which can be generally grouped into the following categories:
  • humanization of the LT 1002 V H domain required only one amino acid from the murine framework sequence whereas the murine V L framework domain, three or five murine residues had to be retained to achieve binding equivalent to the murine parent LT 1002.
  • Binding affinity Biacore measurements of IgG binding to a SlP coated chip showed that the variants LT 1004 or LT 1006 exhibited binding affinity in the low nanomolar range similar to chMAb SlP as shown in Figure 11.
  • the humanized variants LT 1007 and LT 1009 in which the cysteine residue was replaced with alanine exhibited a binding affinity in the picomolar range similar to the murine parent LT 1002 (SphingomabTM).
  • E. coli StB 12 containing the pATH1009 plasmid has been deposited with the American Type Culture Collection (deposit number PTA-8421).
  • CHO cell line LHl 275 transfected with DNA plasmid pATH1009 has also been deposited with the American Type Culture Collection (deposit number PTA-8421).
  • Seeding density is determined for optimal yield.
  • Duration of culture in the bioreactor expected to be 8 to 14 days.
  • CNV lesion volumes are represented as means iLSEM.
  • Table 8 Reduction in macrophage infiltration in the retina by treatment with humanized monoclonal antibody to SlP
  • the objective of this study was to determine the efficacy of LT 1009, alone and in combination with other anti-cancer agents, to retard the progression of human prostate (DU145) carcinoma tumors grafted subcutaneous (sc) and established in female Ncr (nu/nu) mice.
  • mice were implanted sc near the right flank with one fragment per mouse of DU145 tumor from an in vivo passage. All treatments were initiated the day when 60 mice in each experiment established tumors ranging in size from approximately 100 to 200 mm .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2007/082647 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate Ceased WO2008070344A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
BRPI0718118A BRPI0718118A2 (pt) 2006-10-27 2007-10-26 composições e métodos para ligação de sphingosine-1-fosfato
CN200780048665.8A CN101679506B (zh) 2006-10-27 2007-10-26 用于结合鞘氨醇-1-磷酸的组合物和方法
PL07871262T PL2087002T3 (pl) 2006-10-27 2007-10-26 Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
EP07871262.7A EP2087002B1 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
DK07871262.7T DK2087002T3 (da) 2006-10-27 2007-10-26 Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
ES07871262.7T ES2524059T3 (es) 2006-10-27 2007-10-26 Composiciones y procedimientos de unión a esfingosina-1-fosfato
AU2007329759A AU2007329759B2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
CA002667574A CA2667574A1 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
SI200731525T SI2087002T1 (sl) 2006-10-27 2007-10-26 Sestavki in postopki za vezavo sfingozin-1-fosfata
MX2009004532A MX2009004532A (es) 2006-10-27 2007-10-26 Composiciones y metodos para unir esfingosina-1-fosfato.
JP2009534885A JP5795833B2 (ja) 2006-10-27 2007-10-26 スフィンゴシン−１−リン酸と結合させるための組成物および方法
US12/258,346 US8222373B2 (en) 2006-10-27 2008-10-24 Humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,353 US7956173B2 (en) 2006-10-27 2008-10-24 Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate
US12/258,337 US8067549B2 (en) 2006-10-27 2008-10-24 Humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,355 US8025877B2 (en) 2006-10-27 2008-10-24 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,383 US8026342B2 (en) 2006-10-27 2008-10-24 Compositions and methods for binding sphingosine-1-phosphate
IL198379A IL198379A (en) 2006-10-27 2009-04-26 Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85497106P 2006-10-27 2006-10-27
US60/854,971 2006-10-27

Publications (3)

Publication Number Publication Date
WO2008070344A2 true WO2008070344A2 (en) 2008-06-12
WO2008070344A9 WO2008070344A9 (en) 2008-08-28
WO2008070344A3 WO2008070344A3 (en) 2008-11-20

Family

ID=39492938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082647 Ceased WO2008070344A2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate

Country Status (18)

Country Link
US (6) US7829674B2 (enExample)
EP (1) EP2087002B1 (enExample)
JP (2) JP5795833B2 (enExample)
KR (1) KR101581279B1 (enExample)
CN (2) CN104650225B (enExample)
AU (1) AU2007329759B2 (enExample)
BR (1) BRPI0718118A2 (enExample)
CA (1) CA2667574A1 (enExample)
DK (1) DK2087002T3 (enExample)
ES (1) ES2524059T3 (enExample)
IL (1) IL198379A (enExample)
MX (1) MX2009004532A (enExample)
PL (1) PL2087002T3 (enExample)
PT (1) PT2087002E (enExample)
RU (1) RU2460541C2 (enExample)
SI (1) SI2087002T1 (enExample)
WO (1) WO2008070344A2 (enExample)
ZA (1) ZA200902860B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108633A3 (en) * 2008-02-25 2009-12-03 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
WO2010001251A3 (en) * 2008-07-02 2010-03-11 Argen-X B.V. Camelid derived antigen binding polypeptides
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
US20100330080A1 (en) * 2008-07-02 2010-12-30 Torsten Dreier Antigen binding polypeptides
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies
WO2012015758A3 (en) * 2010-07-30 2012-03-22 Saint Louis University Methods of treating pain
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US9181331B2 (en) 2008-04-05 2015-11-10 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US9862751B2 (en) 2013-01-15 2018-01-09 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein peptides
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2008055072A2 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
AU2009322185A1 (en) * 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100292443A1 (en) * 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
PT2462158T (pt) 2009-08-06 2018-02-23 H Hoffnabb La Roche Ag Método para melhorar a remoção de vírus na purificação de proteínas
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
WO2011109650A1 (en) * 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
US9102718B2 (en) * 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
US20130344087A1 (en) * 2010-06-06 2013-12-26 Roger A. Sabbadini Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors
EP2646047A2 (en) * 2010-12-01 2013-10-09 Universität Zürich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
JP5766958B2 (ja) * 2011-01-21 2015-08-19 オリンパス株式会社 顕微鏡システム、情報処理装置、及び情報処理プログラム
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
EP2742337B1 (en) 2011-08-19 2016-05-04 Malvern Instruments Ltd Dual-mode characterization of particulates
ES2600154T3 (es) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anticuerpos antiteofilina y métodos de uso
CA2871112C (en) * 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089996B1 (en) 2014-01-03 2021-07-28 F. Hoffmann-La Roche AG Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
CA2966764C (en) * 2014-11-06 2022-10-18 Merck Patent Gmbh Activated carbon for the removal of leachables and/or extractables
US9754383B1 (en) * 2014-12-22 2017-09-05 Flagship Biosciences, Inc. Automated methods for assessment of celiac disease
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CN109328018A (zh) 2016-12-15 2019-02-12 雀巢产品技术援助有限公司 调节伴侣动物体内的磷或酶的组合物和方法
CA3060080C (en) 2017-04-14 2024-01-23 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary fibrosis
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension

Citations (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937201A (en) 1958-09-02 1960-05-17 Huels Chemische Werke Ag Process for the production of azelaic acid
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6329511B1 (en) 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US20020078757A1 (en) 2000-06-30 2002-06-27 Jacqueline Hines Surface-acoustic-wave pressure sensor and associated methods
US6479284B1 (en) 1998-03-13 2002-11-12 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6500931B1 (en) 1992-11-04 2002-12-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US20030166871A1 (en) 1997-12-05 2003-09-04 The Scripps Research Institute Humanization of murine antibody
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2007053447A2 (en) 2005-10-28 2007-05-10 Lpath, Inc. Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
SE455445B (sv) 1984-08-28 1988-07-11 Pharmacia Ab Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik
EP0173648A3 (en) 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
DE3741056A1 (de) 1987-12-04 1989-08-24 Behringwerke Ag Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung
US5248824A (en) 1990-12-31 1993-09-28 The Biomembrane Institute Method of preparing N,N,N-trimethylsphingosine
US5137919A (en) 1990-12-31 1992-08-11 Biomembrane Institute Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5677288A (en) 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5260288A (en) 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
CA2176220A1 (en) 1993-11-15 1995-05-26 Elizabeth Anne Woodcock A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
AU691886B2 (en) 1994-02-02 1998-05-28 Transave, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5585476A (en) 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5667337A (en) 1995-09-15 1997-09-16 Lazes; Richard J. Rotating containment and repelling boom and method for confining a material floatable on a liquid surface
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JPH09110722A (ja) 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (de) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
KR100468306B1 (ko) 1996-07-19 2005-01-27 다카라 바이오 가부시키가이샤 스핑고지질 및 스핑고지질 유도체의 제조방법
US6140060A (en) 1996-12-12 2000-10-31 Chun; Jerold J. M. Cloned lysophosphatidic acid receptors
US5919687A (en) 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
WO1998040349A1 (en) 1997-03-12 1998-09-17 Takara Shuzo Co., Ltd. Sphingosine analogues
ATE489633T1 (de) 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
US6740512B1 (en) 1997-08-11 2004-05-25 Memorec Biotec Gmbh Neutral sphingomyelinase
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
AU9002298A (en) 1997-09-11 1999-03-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6057126A (en) 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
WO1999038983A1 (en) 1998-01-29 1999-08-05 Smithkline Beecham Plc Novel sphingosine-1 phosphate lyase
CA2320117A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
EP1055682B1 (en) 1998-02-16 2004-10-13 The Kitasato Institute Novel substances kf-1040 and process for producing the same
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
US6130067A (en) 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
EP1235913A2 (en) 1998-05-26 2002-09-04 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
DE19828850A1 (de) 1998-06-27 1999-12-30 Gvs Ges Fuer Erwerb Und Verwer Sphingolipid-Desaturase
ES2316188T3 (es) 1998-06-29 2009-04-01 Children's Hospital Los Angeles Tratamiento de transtornos hiperproliferativos.
DE19847149A1 (de) 1998-10-13 2000-04-20 Max Planck Gesellschaft Pseudo-Ceramide
DK1140170T3 (da) 1999-01-05 2006-10-23 Univ Southern Australia Antistoffragmenter til topisk behandling af öjensygdomme
WO2000052173A2 (en) 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
AU2856499A (en) 1999-03-25 2000-10-16 Kitasato Institute, The Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
WO2000058448A1 (en) 1999-03-26 2000-10-05 Takara Shuzo Co., Ltd. Ceramidase gene
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
JP2000293181A (ja) 1999-04-12 2000-10-20 Daiichikosho Co Ltd 歌詞画像描出機能に特徴を有するカラオケ装置
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
EP1192247B9 (en) 1999-05-13 2007-10-31 Johnson & Johnson Pharmaceutical Research and Development LLC Sphingosine kinase enzyme
DE19924148A1 (de) 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinasehemmer
WO2001004139A2 (en) 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
IT1307786B1 (it) 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
AU1020201A (en) 1999-10-28 2001-05-08 Warner-Lambert Company Human sphingosine kinase gene
AU1548101A (en) 1999-11-24 2001-06-04 Sagami Chemical Research Center Sphingosine derivatives
AU2001233086A1 (en) 2000-01-28 2001-08-07 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
EP1257559A1 (en) 2000-02-07 2002-11-20 Merck & Co., Inc. Mammalian sphingosine-1-phosphate phosphatase
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
AU2001238283C1 (en) 2000-02-14 2006-02-02 Curagen Corporation Sphingosine kinases
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
AU2001247755A1 (en) 2000-03-23 2001-10-03 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
CA2402769A1 (en) 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
AU2001255477A1 (en) 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US20030125533A1 (en) 2000-10-06 2003-07-03 Sophia Kossida Regulation of human sphingosine kinase-like protein
US20020150582A1 (en) 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
WO2006014802A2 (en) * 2004-07-27 2006-02-09 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 1
SI1812797T1 (sl) * 2004-10-28 2013-06-28 Lpath, Inc. Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni
US20080213274A1 (en) 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2008055072A2 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions

Patent Citations (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937201A (en) 1958-09-02 1960-05-17 Huels Chemische Werke Ag Process for the production of azelaic acid
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816397A (en) 1983-03-25 1989-03-28 Celltech, Limited Multichain polypeptides or proteins and processes for their production
EP0120694B1 (en) 1983-03-25 1993-07-21 Celltech Therapeutics Limited Processes for the production of multichain polypeptides or proteins
EP0125023B1 (en) 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1986001533A1 (en) 1984-09-03 1986-03-13 Celltech Limited Production of chimeric antibodies
EP0194276B1 (en) 1984-09-03 1993-08-11 Celltech Therapeutics Limited Production of chimeric antibodies
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0239400B1 (en) 1986-03-27 1994-08-03 Medical Research Council Recombinant antibodies and methods for their production
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0519596A1 (en) 1991-05-17 1992-12-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6639055B1 (en) 1991-06-14 2003-10-28 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6500931B1 (en) 1992-11-04 2002-12-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US20030166871A1 (en) 1997-12-05 2003-09-04 The Scripps Research Institute Humanization of murine antibody
US6479284B1 (en) 1998-03-13 2002-11-12 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6329511B1 (en) 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US20020078757A1 (en) 2000-06-30 2002-06-27 Jacqueline Hines Surface-acoustic-wave pressure sensor and associated methods
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US6881546B2 (en) 2000-12-22 2005-04-19 Medlyte, Inc., Sdsu Heart Institute Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2007053447A2 (en) 2005-10-28 2007-05-10 Lpath, Inc. Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
US20070148168A1 (en) 2005-10-28 2007-06-28 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions

Non-Patent Citations (301)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Immunology", vol. 1, 2, 1991, WILEY-INTERSCIENCE
"Immunobiology", 2001, GARLAND PUBLISHING
"Michels, Retinal Detachment 2nd Edition", 1997, pages: 641 - 771
"Pluckthun in The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
"Remington's Pharmaceutical Sciences", 1980
ABU EL-ASRAR, AM J OPHTHALMOL, vol. 138, 2004, pages 401 - 11
ADAM ET AL., J. BIO CHEM, vol. 271, 1996, pages 14617 - 14622
AKIYAMA ET AL., J CELL PHYSIOL, vol. 207, 2006, pages 407 - 12
ALLENDE; PROIA, BIOCHIM BIOPHYS ACTA, vol. 1582, 2002, pages 222 - 7
ALLENDE; PROIA, BIOCHIM BIOPHYS ACTA, vol. 582, 2002, pages 222 - 7
AMBATI ET AL., SURV OPHTHALMOL, vol. 48, 2003, pages 257 - 93
AMIN; PUKLIN; FRANK, INVEST OPHTHALMOL VIS SCI, vol. 35, 1994, pages 3178 - 88
AN, ANN N Y ACAD SCI, vol. 905, 2000, pages 25 - 33
AN; GOETZL; LEE, J. CELL BIOCHEM, vol. 30/31, 1998, pages 147 - 157
ANDREWS ET AL., OPHTHALMOL VIS SCI, vol. 40, 1999, pages 2683 - 9
ANDRIEU-ABADIE ET AL., FASEB J., vol. 13, 1999, pages 1501 - 1510
ANTIBODIES: "A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
ARMULIK; ABRAMSSON; BETSHOLTZ, CIRC RES, vol. 97, 2005, pages 512 - 23
ASAHARA ET AL., CIRC RES, vol. 83, 1998, pages 233 - 40
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BARONI ET AL., N ENGL J MED., vol. 354, no. 25, 2006, pages 2667 - 76
BAUDHUIN ET AL., FASEB J, vol. 18, 2004, pages 341 - 3
BAUDHUIN ET AL., FASEB J, vol. 18, 2004, pages 341 - 343
BECERRIL ET AL., OPHTHALMOLOGY, vol. 112, 2005, pages 2238
BENJAMIN, L.E.; I. HEMO; E. KESHET, DEVELOPMENT, vol. 125, no. 9, 1998, pages 1591 - 8
BENJAMIN; HEMO; KESHET, DEVELOPMENT, vol. 125, 1998, pages 1591 - 8
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BERGERS; SONG, NEURO-ONCOL, vol. 7, 2005, pages 452 - 64
BOHLER ET AL., NEPHROL DIAL TRANSPLANT, vol. 19, 2004, pages 702 - 13
BOHLER ET AL., TRANSPLANTATION, vol. 79, 2005, pages 492 - 5
BOULTON ET AL., BR J OPHTHALMOL, vol. 81, 1997, pages 228 - 233
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRINK ET AL., BLOOD, vol. 99, no. 8, 15 April 2002 (2002-04-15), pages 2828 - 2834
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
BROWN ET AL., N ENG MED, vol. 355, 2006, pages 1432 - 44
BRUGGERMANN, YEAR IN IMMUNE., vol. 7, 1993, pages 33
BUTRUS ET AL., AM J OPHTHALMOL, vol. 119, 1995, pages 236 - 237
BUTT; LAURENT; BISHOP, EUR J CELL BIOL, vol. 68, 1995, pages 330 - 5
BYLSMA; GUYMER, CLIN EXP OPTOM, vol. 88, 2005, pages 322 - 34
CABILLY; MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851
CALDER ET AL., INVEST OPHTHALMOL VIS SCI, vol. 40, 1999, pages 2019 - 24
CANATAROGLU ET AL., OCUL IMMUNOL INFLAMM, vol. 13, 2005, pages 375 - 81
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CARTER ET AL., BIOITECHNALOGY, vol. 10, 1992, pages 163 - 167
CASSIDY ET AL., BR J OPHTHAMOL, vol. 82, 1998, pages 181 - 85
CHAE ET AL., J CLIN INVEST, vol. 114, 2004, pages 1082 - 9
CHAMPE ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 1388 - 1394
CHATTERJEE, ADV. LIPID RES., vol. 26, 1993, pages 25 - 46
CHO; URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
CHOTHIA,C. ET AL.: "Domain association in immunoglobulin molecules. The packing of variable domains", J MOL. BIOL., vol. 186, 1985, pages 651 - 663
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CIULLA ET AL., CURR OPIN OPHTHALMOL, vol. 12, 2001, pages 442 - 9
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLAUS ET AL., CURR DRUG TARGETS, vol. 1, 2000, pages 185 - 205
CLOTHIA ET AL., J. MOL. BIOL, vol. 186, 1985, pages 651
COUSINS ET AL., ARCH OPHTHALMOL, vol. 122, 2004, pages 1013 - 8
CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
CUVLILIER ET AL., NATURE, vol. 381, 1996, pages 800 - 803
DART ET AL., EYE, vol. 17, 2003, pages 886 - 92
DAS; COOK; SPENCE, BIOCHIM BIOPHYS ACTA, vol. 777, 1984, pages 339 - 342
DAVAILLE ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 34268 - 34633
DENK ET AL., CURR EYE RES, vol. 27, 2003, pages 35 - 44
DESMOULIERE ET AL., JCELL BIOL, vol. 122, 1993, pages 103 - 111
DEUTSCHMAN ET AL., AM HEART J., vol. 146, no. 1, July 2003 (2003-07-01), pages 62 - 8
DI GIROLAMO ET AL., INVEST OPHTHALMOL VIS SCI, vol. 47, 2006, pages 2430 - 7
DOBROWSKY, CELL SIGNAL, vol. 12, 2000, pages 81 - 90
DOHERTY ET AL., BIOCONJUG CHEM, vol. 16, 2005, pages 1291 - 8
DOUGHERTY ET AL., CORNEA, vol. 15, 1996, pages 537 - 540
DRESSLER; MATHIAS; KOLESNICK, SCIENCE, vol. 255, 1992, pages 1715 - 1718
EICHLER ET AL., CURR PHARM DES, vol. 12, 2006, pages 2645 - 60
ELJARRAT-BINSTOCK; DOMB, CONTROL RELEASE, vol. 110, 2006, pages 479 - 89
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688
ERBER ET AL., FASEB J, vol. 18, 2004, pages 338 - 40
ERBER ET AL., FASEB J, vol. 18, 2004, pages 338 - 40.32
ESPINOSA-HEIDMANN ET AL., INVEST OPHTHALMOL VIS SCI, vol. 44, 2003, pages 3586 - 92
FELINSKI; ANTONETTI, CURR EYE RES, vol. 30, 2005, pages 949 - 57
FINI, PROG RETIN EYE RES, vol. I8, 1999, pages 529 - 551
FOLGER ET AL., INVEST OPHTHALMOL VIS SCI, vol. 42, 2001, pages 2534 - 2541
FONTANA ET AL., OPHTHALMOLOGY, vol. 113, 2006, pages 930 - 936
FOOTE, J.; WINTER,G.: "Antibody framework residues affecting the conformation of the hypervariable loops", J MOL. BIOL., vol. 224, 1992, pages 487 - 499
FORRESTER, NAT MED, vol. 9, 2003, pages 1350 - 1
FRENCH ET AL., CANCER RES, vol. 63, 2003, pages 5962 - 5969
FREYBERGER ET AL., EXP CLIN ENDOCRINOL DIABETES, vol. 108, 2000, pages 106 - 109
GARDELL, S.E.; DUBIN, A.E.; CHUN, J., TRENDS MOL MED, vol. 12, 2006, pages 65 - 75
GARIANO; GARDNER, NATURE, vol. 438, 2005, pages 960 - 6
GARIANO; GARDNER, NATURE, vol. 438, 2005, pages 960 - 6.50
GERHARDT, H.; C. BETSHOLTZ, CELL TISSUE RES, vol. 314, no. 1, 2003, pages 15 - 23
GERHARDT; BETSHOLTZ, CELL TISSUE RES, vol. 14, 2003, pages 15 - 23
GERHARDT; BETSHOLTZ, CELL TISSUE RES, vol. 314, 2003, pages 15 - 23
GHATE; EDELHAUSER, EXPERT OPINION, vol. 3, 2006, pages 275 - 287
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
GORIN ET AL., MOL VIS, vol. 5, 1999, pages 29
GRAGOUDAS ET AL., N ENGL J MED, vol. 351, 2004, pages 2805 - 16
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
GROSSKREUTZ ET AL., MICROVASC RES, vol. 58, 1999, pages 128 - 36
GROSSNIKLAUS ET AL., MOL VIS, vol. 8, 2002, pages 119 - 26
GROSSNIKLAUS ET AL., MOL VIS, vol. 8, 2003, pages 119 - 26
GROSSNIKLAUS ET AL., OPHTHALMOLOGY, vol. 101, 1994, pages 1099 - 111
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368
GRYZIEWICZ, ADV DRUG DELIV REV, vol. 57, 2005, pages 2092 - 8
GUO ET AL., AM J PATHOL, vol. 162, 2003, pages 1083 - 93
GUO ET AL., AM J PATHOL, vol. 162, no. 4, 2003, pages 1083 - 93
GUSS ET AL., EMBO J., vol. 5, 1986, pages 15671575
HAGEMAN ET AL., PROC NATL ACAD SCI U S A, vol. 102, 2005, pages 7227 - 32
HAIMOVITZ-FRIEDMAN ET AL., J. EXP. MED, vol. 180, 1994, pages 525 - 535
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HAMA ET AL., J BIOL CHEM., vol. 279, no. 17, 23 April 2004 (2004-04-23), pages 17634 - 9
HANNUN ET AL., ADV. LIPID RES., vol. 25, 1993, pages 27 - 41
HANNUN; BELL, ADV. LIPID RES., vol. 25, 1993, pages 27 - 41
HANNUN; OBEIN, TRENDS IN BIOL. SCI., vol. 20, 1995, pages 72 - 76
HARADA ET AL., PROG IN RETINAL AND EYE RES, vol. 25, 2006, pages 149 - 164
HARILAOS ET AL.: "Erythema Multiforme, Stevens Johnson Syndrome, and Toxic Epidermal Necrolysis", 2005, ELESEVIER MOSBY PHILADELPHIA
HARRIS; CHESS, NAT REV DRUG DISCOV, vol. 2, 2003, pages 214 - 21
HEGDE ET AL., TRANSPLANTATION, vol. 79, 2005, pages 23 - 31
HEMANDEZ ET AL., CIRC. RES., vol. 86, 2000, pages 198 - 204
HEYMANS ET AL., AM J PATHOL, vol. 166, 2005, pages 15 - 25
HLA, T., SEMIN CELL DEV BIOL, vol. 15, 2004, pages 513 - 2
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOLLMGER ET AL., PROC. NAT. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381
HUEBER ET AL., INT. OPHTHALMOL, vol. 20, 1996, pages 345 - 350
HUGHES; CHAN-LING, INVEST OPHTHALMOL VIS SCI, vol. 4, 2004, pages 2795 - 806
HUGHES; CHAN-LING, INVEST OPHTHALMOL VIS SCI, vol. 45, 2004, pages 2795 - 806
HWANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030
IGARASHI, ANN. N.Y. ACAD. SCI., vol. 845, 1998, pages 19 - 31
IGARASHI, J. BIOCHEM, vol. 122, 1997, pages 1080 - 1087
IGARASHI, J., BIOCHEM., vol. 122, 1997, pages 1080 - 1087
IKEDA ET AL., AM J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL, vol. 279, 2000, pages G304 - G310
ING ET AL., OPHTHALMOLOGY, vol. 105, 1998, pages 1855 - 1865
ISHIBASHI ET AL., ARCH OPHTHALMOL, vol. 113, 1995, pages 227 - 31
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551
JERDAN ET AL., OPHTHALMOLOGY, vol. 96, 1989, pages 801 - 10
JESTER ET AL., CORNEA, vol. 1, 1997, pages 177 - 187
JESTER ET AL., EXP EYE RES, vol. 77, 2003, pages 581 - 592
JO ET AL., AM J PATHOL, vol. 168, no. 6, 2006, pages 2036 - 53
JOHNSON ET AL., EXP EYE RES, vol. 70, 2000, pages 441 - 9
JOLLY ET AL., BLOOD, vol. 105, 2005, pages 4736 - 42
JOLLY ET AL., J EXP MED, vol. 199, 2004, pages 959 - 70
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JORDAN, CARDIOVASC RES, vol. 43, 1999, pages 860 - 78
JOUSSEN ET AL., FASEB J, vol. 17, 2003, pages 76 - 8
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTE OF HEALTH
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, pages: 647 - 669
KABAT, EA, PHARMACOL REV, vol. 34, 1982, pages 23 - 38
KAUR; KANWAR, DRUG DEVELOP INDUSTRIAL PHARMACY, vol. 28, 2002, pages 473 - 493
KAWASAKI ET AL., J OPHTHALMOL, vol. 84, 2000, pages 1191 - 3
KENT; SHERIDAN, MOL VIS, vol. 9, 2003, pages 747 - 55
KIM ET AL., J. BIOL. CHEM., vol. 266, no. 1, 1991, pages 484 - 489
KIRA ET AL., GRAEFES ARCH CLIN EXP OPHTHALMOL, vol. 236, 1998, pages 702 - 8
KLEIN ET AL., SCIENCE, vol. 308, 2005, pages 385 - 9
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
KOLESNICK, TRENDS BIOCHEM SCI, vol. 24, 1999, pages 224 - 5
KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
KRAG ET AL., ACTA OPHTHALMOL, vol. 70, 1992, pages 530
KRONKE, CHEM PHYS LIPIDS, vol. 102, 1999, pages 157 - 66
KWON ET AL., J BIOL CHEM, vol. 276, 2001, pages 10627 - 10633
LA COUR; KIILGAARD; NISSEN, DRUGS AGING, vol. 19, 2002, pages 101 - 33.12
LA HEIJ ET AL., AM J OPHTHAL, vol. 134, 2002, pages 367 - 375
LA HEIJ ET AL., AM J OPHTHALMOL, vol. 134, 2002, pages 367 - 75
LEE ET AL., AM. J. PHYSIOL. CELL PHYSIOL., vol. 278, 2000, pages C612 - C618
LEE ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 264, 1999, pages 743 - 50
LEE ET AL., CORNEA, vol. 20, 2001, pages 238 - 42
LEE ET AL., SCIENCE, vol. 279, 1998, pages 1552 - 1555
LEVADE ET AL., CIRC. RES., vol. 89, 2001, pages 957 - 968
LINDAHL ET AL., SCIENCE, vol. 277, 1997, pages 242 - 5
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
LINGEN, ARCH PATHOL LAB MED, vol. 125, 2001, pages 67 - 71
LIU ET AL., CELL DEV. BIOL., vol. 8, 1997, pages 311 - 322
LIU ET AL., CRIT REV. CLIN. LAB. SCI., vol. 36, 1999, pages 511 - 573
LIU ET AL., CRIT. REV. CLIN. LAB. SCI., vol. 36, 1999, pages 511 - 573
LIU, J BIOL CHEM, vol. 275, 2000, pages 19513 - 20
LIU; REGILLO, CURR OPIN OPHTHALMOL, vol. 15, 2004, pages 221 - 6
LONG ET AL., PROSTAGLANDINS OTHER LIPID MEDIAT, vol. 80, 2006, pages 74 - 80
LUBERTO ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 41128 - 41139
MACEYKA ET AL., BBA, vol. 1585, 2002, pages 192 - 201
MACEYKA ET AL., BBA, vol. 1585, 2002, pages 193 - 201
MARCOVICH ET AL., CURR EYE RES, vol. 25, 2002, pages 17 - 22
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MILSTIEN; SPIEGEL, CANCER CELL, vol. 9, 2006, pages 148 - 150
MOREA ET AL.: "Antibody modeling: implications for engineering and design", METHODS, vol. 20, 2000, pages 267 - 279
MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
MORRISON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
MUNSON ET AL., BIOCHEM., vol. 107, 1980, pages 220
MUTSCH; GREHN, GRAEFES ARCH CLIN EXP OPHTHALMOL, vol. 238, 2000, pages 884 - 91
MYLES ET AL., ADV DRUG DELIV REV, vol. 57, 2005, pages 2D63 - 79
NAGINENI ET AL., J CELL PHYSIOL, vol. 203, 2005, pages 35 - 43
NAVA ET AL., EXP CELL RES, vol. 281, 2002, pages 115 - 127
NETTO ET AL., CORNEA, vol. 24, 2005, pages 509 - 522
NEUBERGER ET AL., NATURE, vol. 312, 1984, pages 604 - 608
NISHISHITA; LIN, J CELL BIOCHEM, vol. 91, 2004, pages 584 - 93
NORATA ET AL., CIRCULATION, vol. 111, 2005, pages 2805 - 2811
OBEID ET AL., SCIENCE, vol. 259, 1993, pages 1769 - 1771
OH ET AL., INVEST OPHTHALMOL VIS SCI, vol. 140, 1999, pages 1891 - 8
OH ET AL., INVEST OPHTHALMOL VIS SCI, vol. 40, 1999, pages 1891 - 8
OHTA ET AL., CANCER RES., vol. 55, 1995, pages 691 - 697
OHTA ET AL., FEBS LETTERS, vol. 355, 1994, pages 267 - 270
OKAMOTO ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 260, 1999, pages 203 - 208
ORAL ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 4836 - 4842
O'SULLIVAN ET AL.: "Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym.", vol. 73, 1981, ACADEMIC PRESS, pages: 147 - 166
OTANI ET AL., OPHTHALMOL VIS SCI, vol. 40, 1999, pages 1912 - 20
PAIK ET AL., GENES DEV, vol. 18, 2004, pages 2392 - 403
PAULEIKHOFF, RETINA, vol. 25, 2005, pages 1065 - 84
PAULEIKHOFF, RETINA, vol. 25, 2005, pages 1065 - 84.14
PLANCK ET AL., CURR EYE RES, vol. 11, 1992, pages 1031 - 9
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
POUMARAS ET AL., KLIN MONATSBL AUGENHEILKD, vol. 212, 1998, pages 356 - 358
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
PYNE ET AL., BIOCHEM. J., vol. 349, 2000, pages 385 - 402
PYNE, BIOCHEM J., vol. 349, 2000, pages 385 - 402
QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
RATH; AGGARWAL, J. CLIN. IMMUNO., vol. 19, 1999, pages 350 - 364
RAZZAQUE ET AL., INVEST OPHTHALMOL VIS SCI, vol. 45, 2004, pages 1174 - 81
REICHRNANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROBAYE ET AL., AM J PATHOL, vol. 138, 1991, pages 447 - 453
ROBBINS ET AL., INVEST OPHTHALMOL VIS SCI, vol. 35, 1994, pages 3649 - 3663
ROSENFELD ET AL., N ENG J MED, vol. 355, 2006, pages 1419 - 31
S6GUI ET AL., J. CLIN. INVEST., vol. 108, 2001, pages 143 - 151
SABBADINI ET AL., BIOCHEM. BIOPHYS. RES. COMM., 1993, pages 193752 - 758
SAISHIN ET AL., JCELL PHYSIOL, vol. 195, no. 2, 2003, pages 241 - 8
SEDDON; CHEN, INT OPHTHALMOL CLIN, vol. 44, 2004, pages 17 - 39
SEDLAKOVA ET AL., TRANSPLANTATION, vol. 79, 2005, pages 297 - 303
See also references of EP2087002A4
SERGEEV ET AL., KOSM. BIOL. AVIAKOSM. MED. (RUSSIAN), vol. 15, 1981, pages 71 - 74
SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225
SHAUNAK ET AL., NAT CHEM BIOL, vol. 2, 2006, pages 312 - 3
SIESS ET AL., IUBMB LIFE, vol. 49, 2000, pages 161 - 171
SIVALINGAM ET AL., ARCH OPHTHALMOL, vol. 108, 1990, pages 869 - 872
SMITHE ET AL., TOXICOLOGICAL SCIENCES, vol. 56, 2000, pages 240 - 249
SNOW ET AL., EUR. J. IMMUNOL., vol. 28, no. 10, 1998, pages 3354 - 3361
SOTOZONO ET AL., CURR EYE RES, vol. 19, 1997, pages 670 - 676
SPAIDE, RF, AM J OPHTHALMOL, vol. 141, 2006, pages 149 - 156
SPEIGEI, FASEB J., vol. 10, 1996, pages 1388 - 1397
SPIEGEL ET AL., BIOCHEMISTRY (MOSCOW), vol. 63, 1998, pages 69 - 83
SPIEGEL ET AL., NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 4, 2003, pages 397 - 407
SPIEGEL S; KOLESNICK R, LEUKEMIA, vol. 16, 2002, pages 1596 - 602
SPIEGEL, S.; MILSTIEN, S.: "Sphingosine-1-phosphate: an enigmatic signaling lipid", NAT REV MOL CELL BIOL, vol. 4, 2003, pages 397 - 407
SQUIRES ET AL., J MOL CELL CARDIOL, vol. 39, 2005, pages 699 - 707
STATON ET AL., INT J EXP PATHOL, vol. 85, no. 5, 2004, pages 233 - 48
STAVRI ET AL., CIRCULATION, vol. 92, 1995, pages 11 - 14
STRAMER ET AL., INVEST OPHTHALMOL VIS SCI, vol. 44, 2003, pages 4237 - 4246
STROM ET AL., INVEST OPHTHALMOL VIS SCI, vol. 46, 2005, pages 3855 - 8
SUGIYAMA ET AL., CARDIOVASCULAR RES., vol. 46, 2000, pages 119 - 125
SULTANA ET AL., CURRENT DRUG DELIVERY, vol. 3, 2006, pages 207 - 217
SUN ET AL., J BIOL CHEM, vol. 269, 1994, pages 16512 - 7
SUN ET AL., J BIOL CHEM, vol. 269, 1994, pages 165I2 - 7
SUN; WEBER, CARDIOVASC RES, vol. 46, 2000, pages 250 - 6
SUN; WEBER, J MOL CELL CARDIOL, vol. 28, 1996, pages 851 - 8
SUOMALAINEN ET AL., AM J PATHOL, vol. 166, 2005, pages 773 - 81
SURNNICHT ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 215, 1982, pages 628 - 637
TAKEDA ET AL., INT. IMMUNOL., vol. 5, 1993, pages 691 - 694
TAKUWA, BIOCHIM BIOPHYS ACTA, vol. 1582, 2002, pages 112 - 120
TEZEL; BORA; KAPLAN, TRENDS MOL MED, vol. 10, 2004, pages 417 - 20
TEZEL; KAPLAN, TRENDS MOL MED, vol. 10, 2004, pages 417 - 20
TGF-BETA;. SAIKA ET AL., AM J PATHOL, vol. 168, 2006, pages 1848 - 60
TM4; MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
TOMASEK ET AL., NAT REV MOL CELL BIOL, vol. 3, 2002, pages 349 - 63
TONNETTI ET AL., J. EXP. MED, vol. 189, 1999, pages 1581 - 1589
TRAUTMANN ET AL., J PATHOL, vol. 190, 2000, pages 100 - 6
TRPATHI ET AL., EXP EYE RES, vol. 63, 1996, pages 339 - 46
TSUTSUMI ET AL., J LEUKOC BIOL, vol. 74, 2003, pages 25 - 32
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
UENO ET AL., OPHTHALMOL VIS SCI, vol. 46, 2005, pages 4097 - 106
URATA ET AL., KOBE J MED SCI, vol. 51, 2005, pages 17 - 27
USUI ET AL., JBIOL CHEM, vol. 279, 2004, pages 12300 - 12311
VADAS; GAMBLE, CIRC. RES., vol. 79, 1996, pages 1216 - 1217
VAN BROCKLYN ET AL., J. CELL BIOL., vol. 142, 1998, pages 229 - 240
VERMA ET AL., CURR EYE RES, vol. 16, 1997, pages 1202 - 8
VIDINOVA ET AL., KLIN MONATSBL AUGENHEILKD, vol. 222, 2005, pages 568 - 571
VINE ET AL., OPHTHALMOLOGY, vol. 112, 2005, pages 2076 - 80
VIRAG; MURRY, AM J PATHOL, vol. 163, 2003, pages 2433 - 40
VISENTIN ET AL., CANCER CELL, vol. 9, no. 3, March 2006 (2006-03-01), pages 225 - 38
VISENTIN, B ET AL., CANCER CELL, vol. 9, 2006, pages 1 - 14
WANG ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 35343 - 50
WASCHOLOWSKI; GIANNIS, DRUG NEWS PERSPECT., vol. 14, 2001, pages 581 - 90
WIJNGAARDEN; COSTER; WILLIAMS, JAMA, vol. 293, 2005, pages 1509 - 13
WITMER ET AL., PROG RETIN EYE RES, vol. 22, 2003, pages 1 - 29
XIA ET AL., CURR BIOL, vol. 10, 2000, pages 1527 - 1530
XIA ET AL., J BIOL CHEM, vol. 274, 1999, pages 33143 - 33147
XIA ET AL., PNAS, vol. 95, 1988, pages 14196 - 14201
YAMAGAMI ET AL., MOL VIS, vol. 11, 2005, pages 632 - 40
YAMAGISHI; IMAIZUMI, INT J TISSUE REACT, vol. 27, 2005, pages 125 - 35
YAMAKAGE ET AL., J EXP MED., vol. 175, no. 5, 1 May 1992 (1992-05-01), pages 1227 - 34
YAMAMOTO ET AL., AM J OPHTHAL, vol. 132, 2001, pages 369 - 377
YAMANAKA ET AL., J BIOL CHEM., vol. 279, no. 52, 24 December 2004 (2004-12-24), pages 53994 - 4001
YAMANAKA ET AL., JBIOL CHEM, vol. 279, 2004, pages 53994 - 54001
YANAGA; WATSON, FEBS LETTERS, vol. 314, 1992, pages 297 - 300
YAO ET AL., OCUL IMMUNOL INFLAMM, vol. 11, 2003, pages 211 - 222
YATOMI ET AL., J. BIOCHEM., vol. 121, 1997, pages 969 - 973
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062
ZARBIN, ARCH OPHTHALMOL, vol. 122, 2004, pages 598 - 614
ZHANG ET AL., BLOOD., vol. 93, no. 9, 1 May 1999 (1999-05-01), pages 2984 - 90
ZHANG ET AL., J. CELL BIOL., vol. 114, 1991, pages 155 - 167
ZHANG ET AL., TRANSPLANTATION, vol. 76, 2003, pages 1511 - 3
ZHENG ET AL., JPN J OPHTHALMOLM, vol. 47, 2003, pages 158 - 65
ZOLA: "Monoclonal Antibodies: A Manual of Techniques", 1987, CRC PRESS, INC., pages: 147 - 158

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
WO2009108633A3 (en) * 2008-02-25 2009-12-03 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US9181331B2 (en) 2008-04-05 2015-11-10 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US9428580B2 (en) 2008-07-02 2016-08-30 Argen-X B.V. Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CN102216328A (zh) * 2008-07-02 2011-10-12 阿尔金-X公司 骆驼科动物来源的抗原结合多肽
EP3061768A1 (en) * 2008-07-02 2016-08-31 arGEN-X N.V. Camelid derived antigen binding polypeptides comprising a vh and vl chain
US20100330080A1 (en) * 2008-07-02 2010-12-30 Torsten Dreier Antigen binding polypeptides
AU2009265278B2 (en) * 2008-07-02 2015-03-19 Argenx Bvba Camelid derived antigen binding polypeptides
US9221918B2 (en) 2008-07-02 2015-12-29 Argen-X B.V. Antigen binding polypeptides
CN107739405A (zh) * 2008-07-02 2018-02-27 阿尔金克斯有限公司 骆驼科动物来源的抗原结合多肽
US9346891B2 (en) 2008-07-02 2016-05-24 Argen-X.N.V. Antigen binding polypeptides
US8524231B2 (en) 2008-07-02 2013-09-03 Argen-X B.V. Antigen binding polypeptides
US9315576B2 (en) 2008-07-02 2016-04-19 Argen-X N.V. Antigen binding polypeptides
WO2010001251A3 (en) * 2008-07-02 2010-03-11 Argen-X B.V. Camelid derived antigen binding polypeptides
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
US8835607B2 (en) * 2010-01-04 2014-09-16 Argen-X B.V. Humanized antibodies
CN105801696A (zh) * 2010-01-04 2016-07-27 阿尔金-X有限公司 人源化抗体
CN102858800A (zh) * 2010-01-04 2013-01-02 阿尔金-X公司 人源化抗体
US9540437B2 (en) 2010-01-04 2017-01-10 Argen-X N.V. Humanized antibodies
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies
US8945549B2 (en) 2010-07-30 2015-02-03 Saint Louis University Methods of treating antinociceptive tolerance
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
JP2013533286A (ja) * 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
WO2012015758A3 (en) * 2010-07-30 2012-03-22 Saint Louis University Methods of treating pain
US9862751B2 (en) 2013-01-15 2018-01-09 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein peptides
US10377800B2 (en) 2013-01-15 2019-08-13 Apitope Technology (Bristol) Limited Myelin oligodendrocyte glycoprotein (MOG) peptide
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility

Also Published As

Publication number Publication date
ZA200902860B (en) 2010-07-28
AU2007329759A1 (en) 2008-06-12
MX2009004532A (es) 2009-09-04
US8026342B2 (en) 2011-09-27
US20100003242A1 (en) 2010-01-07
CN101679506A (zh) 2010-03-24
US8067549B2 (en) 2011-11-29
JP2015134760A (ja) 2015-07-27
PL2087002T3 (pl) 2015-02-27
US7829674B2 (en) 2010-11-09
CN104650225B (zh) 2019-10-01
EP2087002A2 (en) 2009-08-12
JP2010515427A (ja) 2010-05-13
CN101679506B (zh) 2015-02-25
SI2087002T1 (sl) 2014-11-28
US20090130099A1 (en) 2009-05-21
US8222373B2 (en) 2012-07-17
IL198379A0 (en) 2011-08-01
EP2087002B1 (en) 2014-09-24
WO2008070344A3 (en) 2008-11-20
JP6053834B2 (ja) 2016-12-27
JP5795833B2 (ja) 2015-10-14
CA2667574A1 (en) 2008-06-12
CN104650225A (zh) 2015-05-27
EP2087002A4 (en) 2010-06-30
KR20100043137A (ko) 2010-04-28
US20090148443A1 (en) 2009-06-11
AU2007329759B2 (en) 2013-05-30
DK2087002T3 (da) 2014-10-27
US8025877B2 (en) 2011-09-27
PT2087002E (pt) 2014-11-26
ES2524059T3 (es) 2014-12-03
WO2008070344A9 (en) 2008-08-28
BRPI0718118A2 (pt) 2017-05-30
US20090137037A1 (en) 2009-05-28
RU2460541C2 (ru) 2012-09-10
IL198379A (en) 2015-04-30
US7956173B2 (en) 2011-06-07
US20090010922A1 (en) 2009-01-08
RU2009120052A (ru) 2010-12-10
KR101581279B1 (ko) 2015-12-31
US20090130100A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
US8067549B2 (en) Humanized antibodies and compositions for binding sphingosine-1-phosphate
US8444970B2 (en) Compositions and methods for treating ocular diseases and conditions
US20090220523A1 (en) Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
US20080213274A1 (en) Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20140186339A1 (en) Compositions and methods for treating ocular diseases and conditions
AU2013273727A1 (en) Compositions and methods for treating ocular diseases and conditions
AU2016204486A1 (en) Composition and Methods for Treating Ocular Diseases and Conditions
HK1128704A (en) Compositions and methods for binding sphingosine-1-phosphate
HK1128704B (en) Compositions and methods for binding sphingosine-1-phosphate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048665.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871262

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2667574

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 198379

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009534885

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004532

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2832/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007329759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097010728

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009120052

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007871262

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007329759

Country of ref document: AU

Date of ref document: 20071026

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0718118

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090327